Aphena Pharma Solutions competitors

C-Level Executive with demonstrated leadership skills and proven business results in Pharmaceuticals (Branded and Generics), Sales, Marketing, Operations, Business Development, R&D/Regulatory.I'm a creative problem-solver, with a track record of outstanding results through professional and interpersonal skills including strategic vision, team development, people management, prioritization, motivation, decisiveness and grit.

Dr. Ellison has served as our President and Chief Executive Officer since April 2020 and as a Director on our Board since January 2020. Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc. (acquired by Roche); President and Chief Executive Officer of Bond Biosciences, Inc., a biotech start-up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC, a life sciences investment banking firm; Chairman and Chief Executive Officer of Assembly Biosciences, Inc. (formerly Ventrus Biosciences, Inc.); Executive Vice President of Paramount Biosciences LLC, a global drug development and healthcare investment firm; Vice President of Clinical Development of FibroGen, Inc., where he played a key role in the early phase development of roxadustat in anemia for chronic kidney disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo US, Inc.; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc. in the United States. Dr. Ellison previously served as an Independent Board Director for several private and public companies, including Cougar Biotechnology Inc.; ProSanos Corporation; Cormedix Inc., a cardio-renal clinical stage company; and Mt. Cook, a urology-focused company. Dr. Ellison received a Master of Science degree from the London School of Tropical Medicine and Hygiene, and an M.D. from the University of British Columbia.

Jim Emme is a CEO at NOW Foods and is based in Greater Chicago Area. He studied at Purdue University.

Salim Haffar has been President of Aptar Pharma since January 2014. Previously, he served as President of Aptar Pharma's Prescription Division and Co-President of Valois Group and President of Valois' Pharma division. Prior to 2008, Salim held various sales and marketing positions within the Company's Valois Pharma division in France.

Gregory Pulido is a Chairman and Chief Executive Officer at HUMCO and is based in Austin, Texas. He studied at Arizona State University.

Chad Holzer is a President, Image Transfer Technologies at Flint Group and Chief Executive Officer at Accupac and is based in Philadelphia, Pennsylvania. He has worked as Global Business Director - Specialty Monomers at Dow, Global Vice President and General Manager at Flint Group, and North American Business Director; Acrylics & Plexiglas Materials at Dow. Chad attended Harvard Business School between 2007 and 2009 and Cornell University between 1998 and 2002.